Introduction
Condylomata acuminata and cancer are ancient diseases.' The first descriptions of condyloma were given by ancient Roman physicians.2 It was realised early on that condyloma was a venereal disease, and it has been connected with syphilis and, later, homosexuality.3 It was not until 1954 that the true nature of transmission was elucidated. American soldiers in Korea developed condyloma after having sexual intercourse with indigenous women. Four to six weeks after their homecoming their wives developed condyloma. 4 The viral aetiology was established in 1968, when viral particles were identified in genital warts,s and 10 years ago it was found that the particles were strains of human papillomavirus other than the strain that causes verruca vulgaris.6 Today more than 60 types of the virus are known, some of which have several subtypes. ' The clinical importance of some of these types is not clear. Human papillomavirus types 6 and 11 are associated with benign condylomatous lesions and low grade cervical intraepithelial neoplasia, and human papillomavirus types 16 and 18 are associated with cervical intraepithelial neoplasia and invasive cancer. 7 The association between genitoanal human papillomavirus infection and cancer is not new. There are several reports of patients with coexistence of condyloma and malignant neoplasm or cervical intraepithelial neoplasia.i-" Human papillomavirus structural proteins have been found in patients with cervical intraepithelial neoplasia.'2 " DNA hybridisation has shown human papillomavirus types 16 and 18 DNA sequences in lesions of invasive cervical cancer, integrated in the genome of the malignant cells. '4 Although it is now becoming increasingly accepted that some human papillomavirus types are involved in the induction of genital cancers there is no clear epidemiological evidence that they cause cancer." We know of only one large prospective study on the development of malignancy in patients with condyloma,'6 '7 though numerous papers report the recent increase in the incidence of condylomata acuminata. lb
IS
In this study we investigated the development of genital cancer in a large group of patients with condyloma.
Patients and methods
Patients-During 1969-84, 3260 patients with condylomata acuminata were seen at the dermatology department of our hospital. We examined the patients' records and recorded the year of diagnosis, age, and sex. Statistics-The length of follow up was calculated for each patient. This was the time from diagnosis of condyloma until 1985, the last year on line at the cancer registry at the time of the study. The expected number of malignant tumours was estimated on the basis of length of follow up and data on national incidence'9 and prevalence2' of cancers from the registry with a computer program developed specifically for this purpose. 22 The estimate for each patient was calculated by using the age and calendar specific national incidence and deducting the probability of death in that age group for each year the patient was in the study. Finally, the individual probabilities were summed. This method has been described in detail elsewhere.2 Regional differences were ignored.
After the ratio between the observed and expected number of malignancies had been estimated, significance and confidence analysis was performed, assuming the variable to have a Poisson distribution. All other statistics and tabulations were done with the SPSS statistical package under the OS/2 operating system.
Results
Among the 3260 patients with condyloma, 27 malignancies were diagnosed at the same time as or after condyloma was diagnosed (table I) . On the basis of the Swedish national incidence data 2549 males and 711 females in the general population would be expected to have 13 4 and 5 6 malignancies respectively. As compared with morbidity in the general population, the morbidity due to cancer produced a relative risk of 1 -6 (95% confidence interval 1-0 to 2 5) for males and 0 9 (0 2 to 2-1) for females. Only 0 6 invasive cervical cancers were expected in the patient group, but one case was observed (relative risk 1-8; 95% confidence interval 0 to 10-1). Nine genitourinary cancers were observed in males, but only 3 4 were expected (2 6; 1-2 to 5-0). Table II gives the characteristics of the genitourinary tumours in males and the time interval to diagnosis after diagnosis of condyloma. Cervical carcinoma in situ was analysed separately; there were 17 cases, but only 11-5 were expected (1 5; 09 to 2-5).
To investigate further the risk of genitourinary cancer the material was stratified according to length of follow up. A total of 915 (28%) patients were followed up for one to four years, 1351 (41%) for five to nine years, and 994 (30%) for more than 10 years. Table III gives the relative risks.
Discussion
The first epidemiological reports of a possible association between condyloma and cancer go back to 1953, when four cases of vulvar cancer preceded by a condyloma infection were described. Since then more than 60 cases of genital cancer in association with condyloma have been reported.2" Since the development of the DNA hybridisation technique many workers have reported an association between human papillomavirus infection and cervical carcinoma. Human papillomavirus types 16 and 18 are found in up to 90% of patients with cervical carcinoma,24 and it is not known if the remaining 10% really are negative for the virus. It has also been shown that up to a half of BMJ VOLUME 303 4 the 95% confidence interval is 1 7 to 7 8. The results of the study therefore do not oppose our results. The age of the patients was similar in both studies. The average follow up period was longer in our study, in which 30% of the patients were observed for 10 or more years, compared with 13% in the Rochester study. Our method of calculating the expected number of patients with cervical carcinoma in situ is more accurate. Interestingly, the same ratio of women developed cervical carcinoma in situ after condyloma was diagnosed in both studies (17 out of 711 (2-4%) in our study compared with 13 out of 500 (2 6%) in the Rochester study). The Rochester authors estimated the incidence of cervical carcinoma in situ in their population by applying the incidence in 1960-7 to the follow up in person years for patients with condyloma diagnosed during 1950-78. We calculated the expected number of cancers individually for each patient by using age and calendar specific incidence data for the corresponding years. The incidence of cervical carcinoma in situ tends to vary yearly (fig 2) , and a steady increase occurred from 1968.19 The steep rise from 1964 to 1968 was probably due to undernotification during the first years after registration of cervical carcinoma in situ became compulsory, better diagnostic awareness, and true increase in incidence. Although this early rise might have been partly due to undernotification, it is important to use these data when predicting the incidence of cervical carcinoma in situ during that period because it is likely that reporting of the disease to the registry would have been influenced by the same factors. Obviously the quality of the incidence data is of crucial importance and strongly affects the relative risks. Our results indicate that the risk of developing cervical carcinoma in situ might be less than previously thought. The follow up may have been too short, but this is not likely as no increased risk was observed in patients followed up for more than 10 The current study design avoids many of the possible biases that might lead to a false conclusion.30 The most important bias is the Berkson bias,3 in which the joint occurrence of two diseases becomes more likely with selective referral of patients with both conditions. This is unlikely to have had any effect on our results as development of cancer was studied after the development of condyloma. A second bias, the withdrawal bias, occurs when the subjects who remain in the study have a higher frequency of the associated disease. Our study design eliminates this bias. The third bias, diagnostic suspicion, occurs when patients included in the study are evaluated more thoroughly for the putative associated disease. As the association between condyloma and cervical cancer has been suspected for a long time, it cannot be excluded that cervical carcinoma in situ is diagnosed earlier in this patient group. The effects of this bias are minimised, however, by the use of the cancer registry.
It might be argued that the fact that some patients are seen at the gynaecological department leads to a selection among female patients, with relatively fewer patients with condyloma on the portio in this study. We do not believe this bias to be important because many "mild" cases of condyloma are diagnosed in the gynaecology department when the patients attend for something else (abortion, preventive counselling, etc). Also many patients have lesions on the portio diagnosed in the dermatology department, although they are finally treated at the gynaecology department. Walker et al have shown that 50% of women with "external" condyloma also have cervical involvement. 32 Finally, more studies are needed to answer fully the question, does human papillomavirus infection cause cancer? Most studies have suggested that human papillomavirus types 6 and 11 are associated with condyloma while types 16 and 18 are associated with cervical neoplasia. It is therefore important to investigate further the development of cancer in patients with known types of human papillomavirus.
